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In this issue ofCancer Cell, Yang et al. (2008) and Schu¨ller et al. (2008) show that Hedgehog activation in either
multipotent neural stem cells or developmentally restricted progenitors causes only medulloblastomas to
form. These data suggest that some stem cell-derived tumors must commit to a specific lineage in order
to grow.The cellular origins of most solid tumors
are not well understood, in part because
specific markers for the stem, progenitor,
and differentiated cell populations from
which they might arise are often lacking.
Medulloblastomas are central nervous
system (CNS) embryonal tumors com-
posed of primitive-appearing cells that
can differentiate along multiple lineages
(Louis et al., 2007). They arise in the cere-
bellum, but it is not yet clear whether
multipotent stem cells, developmentally
restricted progenitors, or other cells give
rise to these pediatric malignancies. It is
hoped that by defining the cell (or cells)
in which they form and the relationship
between normal development and onco-
genesis, improved therapies can be
developed.
The cerebellar ventricular zone (VZ)
consists of a band of stem and progenitor
cells that line the IVth ventricle of the cer-
ebellum (Figure 1). It gives rise to most cell
types in the cerebellum, including Berg-
mann glia, astrocytes, oligodendrocytes,
and Purkinje neurons (Sillitoe and Joyner,
2007). At one edge of this zone lies the
rhombic lip, which sends forth a stream
of lineage-restricted granule neuron pre-
cursors (GNPs) over the cerebellar sur-face. These proliferate transiently in the
external germinal/granular layer (EGL)
and then migrate inward and differentiate
to form the numerous small neurons of the
internal granule cell layer (IGL).
It has become clear that many molecu-
lar pathways play similar roles in both
cerebellar development and medulloblas-
toma formation. Hedgehog signaling, for
example, drives proliferation of the cere-
bellar EGL and is also activated in both
familial and sporadic medulloblastomas,
most commonly by mutations or deletions
abrogating function of the inhibitory re-
ceptor Patched (Ptc) (Louis et al., 2007;
Pietsch et al., 1997). Transgenic mice
lacking one copy of Ptc develop medullo-
blastomas that appear to arise from prolif-
erations of GNP-like cells in the EGL (Kho
et al., 2004; Oliver et al., 2005), suggesting
that medulloblastomas form in lineage-
committed progenitor cells. However,
this notion must be reconciled with the
fact that medulloblastomas are thought
to differentiate into both glia and neurons,
occasionally even forming melanocytic or
muscle cells (Louis et al., 2007). While
such a broad cellular spectrum could re-
sult from dedifferentiation of a committed
GNP due to the influence of oncogenicCancer Cellmolecular events, it is also possible that
the tumors truly form in multipotent stem
cells with an intrinsic multilineage poten-
tial. Indeed, several studies have sug-
gested that some medulloblastomas ex-
press markers normally found in VZ stem
cells and their descendants, but this is
not proof that the tumors came from
stem cells (Eberhart, 2007).
In this issue of Cancer Cell, Yang et al.
(2008) and Schu¨ller et al. (2008) directly
address the issue of which CNS cells are
capable of being transformed into tumors
by Hedgehog activation. They find that
while neoplasms can be ‘‘initiated’’ when
genetic changes are induced in either
multipotent VZ cells or lineage-committed
cells, tumor masses appear to first form
in the EGL and have a largely GNP-like
phenotype.
Yang and colleagues (2008) use condi-
tional cre-mediated deletion of Ptc in
knockout mice (PtcC/C) to activate the
Hedgehog pathway in eitherGNPsormulti-
potent stem cells. Activation in Math1-
expressing GNPs of the rhombic lip and
EGL resulted ina markedexpansionand in-
appropriate persistence of this progenitor
layer during early postnatal life. Many of
these cells were able to exit the cell cycle,14, August 12, 2008 ª2008 Elsevier Inc. 105
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Previewsmigrate appropriately into the IGL, and
differentiate. Some did not, however, and
by 10–11 weeks of age, medulloblastomas
had formed in all animals. Further temporal
control of Ptc deletion, achieved using
a Math1-CreER mouse, indicated that
Math1-positive cells giving rise todeepcer-
ebellar nuclei and brain stemneuronscould
not generate medulloblastomas, while
those fated to populate the EGL could,
further implicating GNPs as the true cell of
origin. Indeed, activation of Hedgehog
signaling as late as postnatal day 10 was
able to initiate tumor formation in GNPs.
Yang et al. (2008) also activated Hedge-
hog in GFAP-expressing neural stem cells
of the VZ, which give rise to multiple types
of neurons and glia. Increased prolifera-
Figure 1. Hedgehog-Induced
Medulloblastoma in Multipotent and
Lineage-Restricted Cerebellar Cells
Multipotent cells expressing GFAP or Olig2 popu-
late the fetal cerebellar ventricular zone and give
rise to Purkinje cells, Bergmann glia, astrocytes,
and oligodendrocytes. They also generate granule
neuron precursors (GNP) in the rhombic lip that
migrate over the cerebellar surface to form an
external germinal layer of progenitors committed
to differentiate into granule neurons. Activating
Hedgehog signaling in either multipotent stem
cells or GNPs results in the formation of medullo-
blastomas (MB) that express markers of granule
neuron differentiation, but not tumors resem-
bling other glial or neuronal cell types. Activation
of Hedgehog in Purkinje cells fails to generate
tumors.106 Cancer Cell 14, August 12, 2008 ª2008tion of neural stem cells was observed fol-
lowingPtcdeletion, but glia and non-gran-
ule neurons derived from these stem cells
appeared normal. In contrast, marked
changes were present when Ptc-deficient
cells migrated to the rhombic lip and
committed to the granule cell lineage.
Both the rhombic lip and EGL were mas-
sively expanded, and cerebellar tumors
formed rapidly in all animals. The tumors
themselves resembled those generated
when Ptc was deleted in Math1-express-
ing cells, with a similar proliferation index,
capacity for differentiation, and trans-
plantability. Thus, earlier genetic tumor
initiation did not seem to generate an
intrinsically more aggressive neoplasm.
Schu¨ller and colleagues (2008) acti-
vated Hedgehog signaling using a mu-
tated Smoothened receptor (SmoM2).
They also found that aberrant Hedgehog
activation in committed GNPs defined by
expression of Math1 resulted in efficient
generation of medulloblastomas. Crosses
resulting in SmoM2 expression in GNPs
defined by Tlx3 expression yielded similar
results, despite the fact that in Tlx3-cre:
SmoM2 animals, cells activate Hedgehog
signaling after they leave the rhombic lip.
Indeed, the authors were able to induce
tumors in GNPs defined by Gli1 expres-
sion in the EGL up to postnatal day 10 in
Gli1-CreERT2:SmoM2 mice.
Schu¨ller et al. (2008) also generated
medulloblastomas by activating Hedge-
hog signaling in multipotent stem/progen-
itor cells expressing GFAP or Olig2. The
authors demonstrate for the first time
that this latter protein, previously shown
to be expressed in multilineage progenitor
populations in the spinal cord and fore-
brain, also marks a subset of multipotent
cerebellar VZ cells destined to give rise
to oligodendrocytes, Purkinje cells, and
interneurons, as well as granule cells
concentrated in the posterior cerebellar
lobes.
One significant finding in both studies
was the inability of Hedgehog signaling
to induce astrocytomas, oligodendroglio-
mas, or neuronal tumors, despite the fact
that the pathway was activated in multi-
potent stem cells in several brain regions.
Indeed, when Schu¨ller and colleagues
(2008) expressed SmoM2 specifically in
Purkinje neurons, no tumors formed. It
has recently been shown that Hedgehog
activity is required for growth of stem-
like malignant glioma cells (Bar et al.,Elsevier Inc.2007; Clement et al., 2007), but activation
of the pathway, at least by itself, seems
insufficient to generate glial tumors.
A second intriguing finding was the re-
quirement that cells commit to a granule
cell lineage prior to generating fully trans-
formed tumor masses. This appears to
result from an intrinsic property of GNPs
rather than local factors in the cerebellum,
as once murine medulloblastomas
formed, they could be transplanted with
equal efficiency into both cerebellar and
forebrain locations. It has been suggested
that some molecular signals important in
normal cell lineage development function
as lineage dependency/lineage addiction
factors in cancer (Garraway and Sellers,
2006), and it may be that Hedgehog plays
a similar role in at least a fraction of
medulloblastomas.
It is important to remember that the re-
sults presented in these two papers only
reflect oncogenesis driven by Hedgehog
signaling and that the capacity of other
molecular events to cause either multipo-
tent or more restricted cells to form me-
dulloblastomas could be quite different.
Nevertheless, it is now clear that even
tumors made up largely of a single cellular
lineage may well have been initiated in
a multipotent stem or progenitor cell and
that expression studies of the bulk of
tumor cells may not always indicate the
cell of origin.
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resistant mutations in the affinity p
these critical residues provides a
anticipated resistance mutations.
Small-molecule inhibitors targeting the
tyrosine kinases Abl and EGFR have
been spectacularly successful as cancer
drugs (Druker, 2004). However, these
successes have been curtailed by the
appearance of kinase mutants that are
resistant to the inhibitors (Gorre et al.,
2001; Pao et al., 2005). The inhibitors typ-
ically bind to a conserved structural motif,
referred to as an affinity pocket, that is
located in the immediate vicinity of the
ATP binding site. They compete with ATP
for binding to the kinases. Most of the
resistance mutations block inhibitor bind-
ing. A particularly effective and commonly
encountered mutation occurs at a position
referred to as the ‘‘gatekeeper’’ that con-
trols access of inhibitors to the affinity
pocket. The resistance mutations have
now led to the development of second-
generation inhibitors that are effective
against many of the mutant kinases (Bur-
gess and Sawyers, 2006; Druker, 2006;
Kwak et al., 2005). However, targeting
gatekeeper mutant kinases remains a
significant challenge. This situation illus-
trates the general problem of mutation-
induced drug resistance that needs to be
anticipated in all therapeutic strategies.
In recent years, phosphatidylinositol
3-kinase (PI3K) has emerged as an ex-
ceedingly attractive and promising drug
target. The PI3K signaling pathway is
upregulated in most cancers as a resultQian, Y., et al. (2008). Cancer Cell 14, this issue,
123–134.
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of various genetic and epigenetic changes.
PIK3CA, the gene encoding the catalytic
subunit p110a of PI3K, is frequently mu-
tated in cancers of the breast, colon,
endometrium, and prostate (Samuels
et al., 2004). About 80% of these muta-
tions map to one of three hot spots in
the gene. They induce a gain of function
in enzymatic and signaling activity. The
mutant p110a is also oncogenic in cell
culture and in animal model systems,
strongly suggesting that it contributes to
the oncogenic cellular phenotype in hu-
man cancers. Academic and industrial
laboratories have responded to this de-
velopment by generating PI3K inhibitors,
some of which are entering clinical trials
(Marone et al., 2008). Mutations resulting
in inhibitor resistance will surely arise.
Can we apply the lessons learned from
the protein kinases to the lipid kinase
PI3K? This is the question asked in a study
published in the current issue of Cancer
Cell (Zunder et al., 2008).
The recently determined structure of
p110a shows some broad similarities to
that of protein kinases, notably a hydro-
phobic cavity that corresponds to the
affinity pocket of protein kinases (Huang
et al., 2007). Several PI3K inhibitors target
this structural motif and therefore could
be affected by resistance mutations simi-
lar to those found in protein kinases.
These basic similarities guided Zunder
Cancer Cell 1Yang, Z.-J., Ellis, T., Markant, S.L., Read,
T.-A., Kessler, J.D., Bourboulas, M., Schu¨ller,
U., Machold, R., Fishell, G., Rowitch, D.H.,
et al. (2008). Cancer Cell 14, this issue, 135–
145.3-Kinase:
dings from investigating inhibitor-
ol 3-kinase (PI3K). Information on
inhibitors that can overcome the
and colleagues (2008) in their study of
drug resistance in PI3K. The researchers
mutagenized selected residues lining
the p110a affinity pocket, including the
homolog of the gatekeeper, I848. The mu-
tants were tested against several PI3K
inhibitors using an ingenious yeast lethal-
ity test. The assay is based on the fact that
Saccharomyces cerevisiae does not con-
tain class I PI3Ks and that expression
of p110a depletes its essential stores
of phosphatidylinositol 4,5-bisphosphate,
thus interfering with cell replication. Inhi-
bition of p110a activity restores growth
and viability of p110a-expressing S. cere-
visiae (Figure 1). The simplicity and
rapidity of the yeast screen allowed cov-
erage of a sizable number of mutant/
inhibitor combinations, including satura-
tion mutagenesis and diverse inhibitor
chemotypes.
The results of these mutagenesis stud-
ies are both unexpected and instructive.
In contrast to the affinity pockets of pro-
tein kinases, which can accommodate
diverse mutations, the pocket of p110a
is relatively intolerant to change. Most
mutations led to a loss of enzymatic activ-
ity. Gatekeeper mutations were another
surprise: not only did they fail to induce
resistance, most of them were also cata-
lytically inactive or retained only minimal
enzymatic activity. A single residue in
the affinity pocket gave rise to resistant
4, August 12, 2008 ª2008 Elsevier Inc. 107
